title: Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulfate in the control of iron deficiency in pregnant women.
abstract: The relative effectiveness of daily supplementation of iron deficiency during pregnancy using 15 mg/day of iron from iron-bis-glycinate chelate (71 pregnant women), or 40 mg iron from ferrous sulfate (74 pregnant women) was evaluated by measuring hemoglobin, transferrin saturation and serum ferritin, at the beginning of the study (< 20 weeks of pregnancy) and at 20-30 weeks and 30-40 weeks thereafter. Ingestion for 13 weeks or more was considered adequate. Seventy three percent of the Ferrochel consuming group and 35% of the ferrous sulfate consuming group were considered to have taken the treatment adequately. The decrease in levels of all the measured parameters was significantly less pronounced in the group that consumed Ferrochel in spite of the lower treatment dose. Iron depletion was found in 30.8% of the women treated with Ferrochel and in 54.5% of the women than consumed ferrous sulfate. Of the factors responsible for non compliance taste was reported in 29.8% of the ferrous sulfate consumers and none in the groups that consumed Ferrochel. It is concluded that daily supplementation with Ferrochel was significantly more effective, in spite of the lower dose, than supplementation with ferrous sulfate.
authors.affiliation: Sao Paulo University, Sao Paulo, Brazil.
authors.forename: S C
authors.initials: SC
authors.lastname: Szarfarc
authors.forename: L M
authors.initials: LM
authors.lastname: de Cassana
authors.forename: E
authors.initials: E
authors.lastname: Fujimori
authors.forename: E M
authors.initials: EM
authors.lastname: Guerra-Shinohara
authors.forename: I M
authors.initials: IM
authors.lastname: de Oliveira
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000517:prevention & control*; D019587:Dietary Supplements; D005260:Female; D005293:Ferritins / Q000097:blood; D005296:Ferrous Compounds / Q000627:therapeutic use*; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D000090463:Iron Deficiencies; D008137:Longitudinal Studies; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control*; D011446:Prospective Studies; D014168:Transferrin / Q000032:analysis; D016896:Treatment Outcome
chemical_list: D005296:Ferrous Compounds; D006454:Hemoglobins; D007502:Iron Chelating Agents; D014168:Transferrin; C073588:bis-glycino iron II; C020748:ferrous sulfate; D005293:Ferritins; D005998:Glycine